Jim
Christensen MD
•professional
data
•education
and degrees
•licensure
•military
duty
•employment
history
•academic
appointments
•hospital
staff appointments
•community
organizations and awards
•memberships
and associations
•publications
•research
PROFESSIONAL
DATA:top
Allergy and Asthma
Associates
4000 E. Charleston
Blvd #100
Las Vegas, NV 89104
(702) 432-9544 (phone)
(702) 4328011 (fax)
Allergy and Asthma
Associates
8413 W. Lake Mead
Blvd.
Las Vegas, NV 89128
(702) 242-5988 (phone)
(702) 242-5901 (fax)
Allergy and Asthma
Associates
4 Sunset Way Building
A, Suite 3
Henderson, NV 89014
(702) 436-7720 (phone)
(702) 436-7266 (fax)
Wellness Center
2300 S. Rancho Dr.
#205
Las Vegas, NV 89102
(702) 383-2691 (phone)
(702) 388-4186 (fax)
Nevada Access to Research
and Education Society (NARES)
Nevada AIDS Research
and Education Society
2300 S. Rancho Dr.
#203
Las Vegas, NV 89102
(702) 384-9101 (phone)
(702) 384-9109 (fax)
E-mail address: snotdoc@cox.net
UPIN: E
41200
MEDICARE: WJBCQ02
MEDICAID: 2019060
MEDICAL EDUCATION
#: 03101840068
EDUCATION AND DEGREES:top
1974 - 1978
University of California
Urvine, CA
B.A. Chemistry
1977
- 1978 University of CaliforniaIrvine, CAPhysical Science Research
Fellow
1980
- 1984 University of Nevada
School of MedicineReno, NVMedical School
1984
- 1987 Washington University
at St. LouisSt. Louis, MOInternal Medicine,
Internship and Residency
1985
Diplomat, NBME
1987
Diplomat, American
Board of InternalMedicine
1987
- 1989 National Jewish Center
of Immunology and Respiratory MedicineDenver, COFellowship, Allergy
and Immunology
1989
Diplomat, American
Board of Allergy andImmunologyRe-certified 1999
1994
Diplomat, American
Board of UtilizationReview and Quality
Assurance
1997
Fellow, American College
of PhysiciansLICENSURE:
topCalifornia #G059835
04/06/1987Arizona #18649
04/14/1989Nevada #6171
12/01/1990MILITARY DUTY:
top1987 - 1992
Major, U.S. Air Force
ReserveMedical Corps
1988
- 1992 Flight Surgeon120th TFS Colorado
Air National GuardEMPLOYMENT HISTORY:
top1978 - 1979Craps DealerLas Vegas, NV
1979
- 1980 Emergency Medical TechnicianLas Vegas, NV
1984
- 1987 Intern, Junior and
Senior Assistant ResidentDepartment of Internal
MedicineWashington University
of St. LouisSt. Louis, MO
1987
- 1989 Clinical FellowAllergy & Clinical
ImmunologyNational Jewish CenterDenver, CO
1989
– Oct 1990 Private PracticeAllergy and Immunology
AssociatesScottsdale, AZ
Oct.
1990 - Dec. 1990 Urgent Care DepartmentCigna Health Plan of
ArizonaPhoenix, AZ
Dec.
1990 - Dec. 1992 Assistant Professor
of MedicineAssistant Program Director
Department of Internal
Medicine University of Nevada
School of Medicine Las Vegas, NV
Dec.
1992 - Present Allergy and Asthma
AssociatesLas Vegas, NV
April
1999 - Present Co-Founder, NARESLas Vegas, NVACEDEMIC APPOINTMENTS:
top1990 - Present
Clinical Assistant
ProfessorDepartment of Internal
MedicineUniversity of Nevada
School of Medicine
1997
- Present Clinical Associate
ProfessorDepartment of Health
SciencesUniversity of Nevada
Las VegasHOSPITAL STAFF APPOINTMENTS:
topUniversity Medical Center
Las
Vegas, NVValley Hospital Las
Vegas, NVSunrise Medical Center
Las
Vegas, NVSt. Rose Dominican Medical
Center Henderson, NVSt. Rose Dominican–Siena
Campus Henderson, NVSpring Valley Hospital
Medical Center Las Vegas,
NV COMMUNITY ORGANIZATIONS AND AWARDS:
top1991 - 1998
Medical Director, Asthma
Camp
1998
- 2000 President, Board of
Directors Reach Out
1998
- Present Physician at Large
MemberClark County Board
of Health
1999
- Present Chairman, Performance
Improvement Committee
University Medical Center
2000
Leadership Las Vegas,
GraduateLas Vegas Chamber of
Commerce
2000
Humanitarian of the
YearLas Vegas Chamber of
Commerce
2000,
2002 Top Doctor’s
of Las VegasLas Vegas Life Magazine
2000
Physician Member at
LargePerformance Improvement
CommitteeValley Hospital and
Medical CenterLas Vegas, NV
2002
ACP-ASIM Governor, State of
Nevada
2002
Chairman, Department
of MedicineUniversity Medical
CenterLas Vegas, NV
2003
Director of Performance
Improvement
Spring Valley Hospital
Medical Center
Las Vegas, NV
MEMBERSHIPS AND ASSOCIATIONS:top
American College of
Physicians
American Academy of
Allergy and Immunology
American College of
Allergy and Immunology
Clark County Medical
Society
American Academy of
HIV Medicine
PUBLICATIONS:top
Hamilos DL, Christensen
J, Bean DK, Treatment of Churg-Strauss
Syndrome with High-Dose
Intravenous Immunoglobin. JACI 1991;
88:823-4.
Bishop P, Wisnieske
JJ, Christensen J, Hypocomplementemic
Urticarial Vasculitis:
A case report and review of the literature. West
J Med 1992; 159:605-8.
Wisnieske JJ, Baer
AN, Christensen J, et al. Hypocomplementemic Urticarial
Vasculitis Syndrome: A prospective & retrospective study
of 18 patients. Medicine
1995; 74:24-41.
Church JA, Mitchell
WG, Ganzales-gomez I, Christensen J, et al.
Mitochondrial DNA
depletion, near-fatal metabolic acidosis, and liver
failure in an HIV-infected
child treated with combination
antiretroviral therapy.
J Pediatr 2001;138: 748-51.
RESEARCH:top
Deflazacort in mild
Asthma. Investigator. 1988.
566C80 (Mepron) in
Pneumocystis Carinii Pneumonia. Investigator.
1991.
ABT-971. Phase III
Study of the effects of Zileuton, 400 and 600mg
QID compared to Beclomethasone
in asthma. Investigator. Abbott
Laboratories. 1993.
FLTA 2005. A trial
of inhaled Fluticasone MDPI vs. Placebo in
adolescent and adults
with asthma. Investigator. Glaxo Welcome.
1993.
RG-5016T-203. Study
of Azmacort HFA-134a compared to Azmacort
in the treatment of
asthma in children. Investigator. Rhone-Poulenc
Rorer.
RG-5016Y-203. Study
of Azmacort HFA-134a compared to Azmacort
in the treatment of
asthma in adults. Investigator. Rhone-Poulenc
Rorer.
04-3100. Study of
Budesonide nebulizing suspension and Placebo in
asthmatic children
age eight and younger. Investigator. Astra
Pharmaceuticals.
04-3100. Open label
extension. Study of Budesonide nebulizing
suspension and Placebo
in asthmatic children age eight and
younger. Investigator.
Astra Pharmaceuticals.
FLTA-2005. Open label
extension. A trial of inhaled Fluticasone
MDPI vs. Placebo in
adolescent and adults with asthma.
Investigator. Glaxo
Welcome.
Azithromycin. Oral/Intravenous
Azithromycin Treatment of
Cryptosporidiosis
in Patients Whose Disease has not been
Controlled by Conventional
Therapy (066- 167S). Investigator,
Premier Research.
Amphotericin B Lipid
Complex (ABLC) for Companionate Use (A93-
D-01, 339). Investigator,
The Liposomal Company, Inc.
Saquinavir. HIV Proteinase
Inhibitor Saquinavir Ro 31-8959
(SV14604). Investigator,
F. Hoffmann LaRoche Limited.
Saquinavir Ro 31-8959
A Continuation Protocol with Open Label
Saquinavir for HIV-Infected
Patients Who Have Completed a Clinical
Trial with Saquinavir
Treatment (SV 14788). Investigator, F.
Hoffmann LaRoche Limited.
Lamivudine. 3TC (Lamivudine)
Open Label Program (NUCA 3004).
Investigator, Glaxo,
Inc.
Vistide (Cidofovir).
IV Treatment IND Protocol for Relapsing
Cytomegalovirus Retinitis
in Patients with AIDS (GS 95120).
Investigator, Gilead
Sciences.
Albendazole (Eskazole)
for Compassionate Use in Microsporidiosis
(IND 45062). Investigator,
SmithKline Beecham.
Ambisome. Compassionate
Use of Ambisome for Treatment of
Invasive Fungal Infections
in Patients Intolerant to, or with, Disease
Unresponsive to Standard
Antifungal Therapy (95-0-010).
Investigator, Fujisawa
USA.
Nevirapine (Viramune).
An Open Label Non-Randomized Trial to
Evaluate the Tolerability
and safety of Viramune (nevirapine) in
Adult and Pediatric
Patients with Progressive, Symptomatic HIV
Disease. Protocol
1100.859. Investigator, Roxanne.
Viracept. Viracept
Expanded Access Program (Ind# 48.124).
Investigator, Auguron.
Synercid. Open Study
of Synercid (Quinupristin/Delfopristin, RP
59500) for Emergency
Use (Infections Due to Resistant Bacteria
Treatment Failure
or in Treatment Intolerant Patients). Protocol JRV
398. Investigator,
Rhone-Poulenc Rorer.
Indinavir (Crixivan).
A Noncomparative, Multisite, Open-Label, 48
Week Study to Monitor
the Safety and Tolerability of MK-0639
(Indinavir Sulfate)
800mg q8h Administered as Monotherapy or in
Combination with Reverse
Transcriptase Inhibitor Therapy for the
Treatment of HIV-1
Infection in Advanced AIDS Patients (Patients
with CD4 Counts <50cells/mm3
(99-00). Investigator, Merck
and Co., Inc.
Mycobutin (Rifabutin).
An Open-Label Randomized Pharmacological/
Pharmacodynamic study
of mycobutin (Rifabutin) monotherapy, and
in combination with
myambutal (Ethambutal), for prophylactic use in
prevention of Mycobacterium-Avium
Complex (MAC) bacteria in
AIDS patients with
CD4 count < 100mm_. Investigator, Pharmacia.
Nitazoxanide. Open-Label
Compassionate Use of Nitazoxanide for the
treatment Of Cryptosporidiosis
in AIDS patients. Protocol UMD-95-
009. Investigator,
Unimed Pharmaceuticals.
Viracept. An Open-Label
Study to Evaluate Viracept Treatment of
HIV-Infected Children
Who Could Benefit from a Protease Inhibito
Based on Clinical
or Immunologic Status (AG1343-546). Investigator,
Aguoron.
A 1592U89 Open Label
Protocol of Adult Patients with HIV-
Infection (CNAA/3008).
Investigator, Glaxo Wellcome Research &
Development.
Thalidomide. Treatment
of Aphthous Ulcers in a Patient with
Behcet’s Syndrome,
having Failed Steroid and Immunosuppressive
Therapy (IND# 53,970).
Investigator.
Saquinavir. A Randomized
Phase IIIB Comparative Study to Evaluate
Saquinavir Soft Gel
Capsules (SGC) TID Regimen in Combination
with two NRTI’s
Versus Saquinavir Soft Gel Capsules (SGC) BID
Regimen in Combination
with two NRTI’s Versus Saquinavir Soft Gel
Capsules (SGC) BID
plus Nelfinavir BID plus an NRTI in HIV-1
Infected Patients
(NR5520B/M51018). Investigator, F. Hoffmann-La
Roche LTD.
A 1592U89 Open Label
Protocol for Pediatric Patients with HIV
Infection (CNAA/3007).
Investigator, Glaxo Wellcome Research &
Development.
Sustiva (efavirenz).
Expanded Access Program DMP266-903 (IND#
49,465). Investigator,
DuPont Merck.
Thalidomide. Treatment
of Aphthous Ulcers in a Patient with
Behcet’s Syndrome
Having Failed Steroid and Immunosuppressive
Therapy (IND# 54,463).
Investigator.
A Multicenter Open
Label Randomized 24-Week Study to Compare
the Safety and activity
of Indinavir Sulfate 800mg Q8H Versus
1200mg Q12H in HIV-
Infected Individuals Having Plasma Viral RNA
Less Than 400 copies/ml
on Concomitant Therapy with Two
Nucleoside Analogue
Reverse Transcriptase Inhibitors (NRTI) 076-
00. Investigator,
Merck & Company. Preveon Expanded Access
Program for the Treatment
of Patients with AIDS Who Have Failed
Other Antiretroviral
Therapy and have Limited Treatment Options
(GS-52-427). Investigator,
Gilead Sciences.
An Open-Label Multicenter
Study to Assess the Safety and
Antiviral Activity
of a Twice-Daily Dosing Regimen of Viracept
Combined with Two
Reverse Transcriptase Inhibitors in HIV-
Infected, Treatment
Naive Patients (AG13543- 1022). Investigator,
Auguron
Compassionate Use
of Thalidomide in Hypocomplementemic
Urticarial Vasculitis
Syndrome (IND 55,590), Investigator.
The Thalidomide Compassionate
Use Program. Compassionate Use
of Thalidomide in
Adults with HIV-Associated Wasting (W-002).
Investigator, Celgene
Corp. 1998.
Amprenavir (141W94).
Open label protocol for patients with HIV-1
infection who have
experienced treatment failure or are intolerant to
protease therapy,
(PR030010). Investigator, Glaxo Wellcome, Dec.,
1998.
A Phase III trial
to determine efficacy of bivalent AIDSVAX™ B/B
vaccine in adults
at risk for sexually transmitted HIV-1 infection in
North America (VAX004).
Investigator, Vaxgen Inc., March, 1999.
Evaluation of the
safety and antiviral activity of stavudine extended
release Formulation
as compared to stavudine immediate release
formulation, each
as part of potent antiretroviral combination
therapy. (AI455-096).
Investigator, Bristol-Myers Squibb, Oct 1999.
DE 009. A multicenter
randomized placebo controlled phase II study
of the Human Anti-TNF
Antibody D2E7 administered as
subcutaneous injections
in rheumatoid arthritis patients treated with
methotrexate. (LU
200134). Investigator, Knoll Pharmaceutical Comp,
Dec 1999.
O99009 Transdermal
oxybutynin in patients with urge urinary
incontinence: A 12
week multicenter, randomized, double-blind,
placebo-controlled
study with a 12-week open-label, dose-titration,
safety extension.
Watson Laboratories. Investigator, Jan 2000.
Protocol M99-046.
ABT-378/r (ABT-378/ritonavir) Early Access
Program. Investigator,
Abbott Laboratories, Jan 2000.
SNG477. A randomized,
double-blind, multicenter study to evaluate
the effect of adding
either Montelukast Sodium or Salmeterol
Xionafoate to inhaled
Fluticasone in adult asthmatics. Investigator.
Merck and Co. Inc.
A randomized, double-blind,
placebo controlled, parallel-group 12
week trail evaluating
the safety and efficacy of
Salmeterol/Fluticasone
Propionate combination in GR106642X MDI
vs. Salmeterol, Fluticasone
or Placebo in adolescent and adult
subjects with asthma.
Investigator. Glaxo Wellcome. 2000. Protocol
ESS 40001 A Phase
IV, open-label, randomized study to compare the
efficacy and safety
of Epivir/Ziagen/Zerit versus
Epivir/Ziagen/Sustiva
versus Epivir/Ziagen/Agenerase/Norvir for 96
weeks in the treatment
of HIV-1 infected subjects who are
Antiretroviral therapy
naive. Glaxo Wellcome. Investigator, Aug.
2000.
Protocol ESS 40009
Ziagen Optimal Regimen and Resistance
Observational Study.
A Phase IV, Open-label study to assess the
safety and tolerability
of abacavir (Ziagen), in HIV-1 infected
individuals and to
investigate the effect of baseline genotype with
virtual phenotype
on the response to abacavir (Ziagen) in therapy
experienced subjects
in the clinical setting.GlaxoWellcome Research
and Development. Investigator,
Aug 2000.
HMP-3006 A Study of
the Efficacy and Safety of Hydromorphone
Hydrochloride Extended-Release
(HHER) Compared to Placebo in
Patients with Chronic
Pain. Purdue Pharma L.P. Investigator. Jan.
2001.
AI455-110. A Study
to Compare Stavudine (D4T) Extended Release
(ER) versus Conventional
(Immediate Release, IR) Formulations, Each
in Combination with
Lamivudine (3TC) and Efavirenz (EFV) in
Subjects who have
Completed BMS Studies AI455-096 and AI455-
099.Britstol-Myers
Squibb. Investigator Jan 2001.
ESS40013. A Phase
IV Multicenter Study of the Efficacy and Safety
Of 48-Week Induction
Treatment with Trizivir + Efavirenz Followed
by 48-Week Randomized,
Open-Label Maintenance Treatment with
Trizivir ±
Efavirenz in HIV-1 Infected ART Naïve Subjects.
GlaxoSmithKline. Investigator
Mar 2001.
HIV-TE-Evaluation
Project 101. An Evaluation of the Use of the HIV-
Therapy Edge (HIV-TE)
Service in the Management of HIV-Positive
Patients Currently
Failing Antiretroviral Drug Therapy. Intelligent
Therapeutic Solutions,
Inc. Investigator May 2001.
O00011. A Multi-Center,
Randomized, Double-Blind, Placebo-
Controlled Study Comparing
Oxybutynin Transdermal Systems
versus Tolterodine
Long Acting Capsules in Patients with
Overactive Bladder.
Watson Laboratories. Investigator May 2001.
CNA30021. A phase
III, 48 week, randomised, double-blind,
multicentre study
to evaluate the safety and efficacy of abacavir
(ABC) 600mg once-daily(QD)
vs abacavir 300mg BID in combination
with lamivudine (3TC)
(300mg QD) and efavirenz (EFV) (600mg QD)
in antiretroviral
therapy Naive HIV-1 infected subjects.
GlaxoSmithKline. Investigator
2001.
SPORTIF V. Efficacy
and safety study of the oral direct thrombin
inhibitor H376/95
compared with dose-adjusted warfarin (Coumadin)
in the prevention
of stroke and systemic embolic events in patients
with atrial fibrillation.
Astra Zeneca. Investigator. 2001.
N91-00-02-079. Clinical
protocol for a randomized, double-blind,
placebo controlled,
parallel group comparison of the analgesic
activity of valdecoxib
(SC- 65872) 20mg bid versus diclofenac 75mg
bid in patients with
chronic cancer pain. Pharmacia/Pfizer.
Investigator. 2001.
N49-01-02. clinical
protocol for the assessment of the efficacy of
treatment by Celecoxib
200mg QD and 400mg QD on the symptoms
of ankylosing spondylitis
compared to naproxen and placebo.
Investigator. Pharmacia.
2001.
HMR3647A/3014. Randomized,
open-label, multicenter trial of the
safety and effectiveness
of Oral Telithreomycin (Ketek) and
amoxicillin/clavulanic
acid (Augmentin) in outpatients with
respiratory tract
infections in usual care settings. Aventis
Pharmaceuticals, Inc.
Investigator. 2001.
NAVIGATOR Nateglinide/CDJN608B.
A multinational, randomized,
double- blind, placebo-controlled,
forced-titration, 2 X 2 factorial
design study of the
efficacy and safety of long term administration
of nateglinide and
valsartan in the prevention of diabetes and
cardiovascular outcomes
in subjects with impaired glucose tolerance.
Novartis. Investigator.
CLAF237A 2203. A 12
week, multicenter, double-blind, randomized,
parallel- group, dose-ranging
study to assess the efficacy, safety
and tolerability of
LAF237 25mg bid, 25mg, 50mg, 100mg qd
compared to placebo
in patients with type 2 diabetes. Novartis.
Investigator.
SAS40036. Multicenter,
randomized, double blind, double dummy,
parallel group 16
week comparison of asthma control in adolescents
and adults receiving
either Fluticasone Propionate/Salmeterol Diskus
100/50mcg bid, Fluticasone
Propionate Diskus 100mcg bid, Salmeterol
50mcg bid or montelukast
10mg qd. GlaxoSmithKline. Investigator.
M016455P/3003. A multicenter,
open label, randomized, parallel group
study to assess the
long term safety, performance, and efficacy of
fexofenadine compared
to montelukast in subjects with asthma.
Aventis. Investigator
April 2002.
SAS30022. A randomized,
double-blind, placebo-controlled, parallel-
group, 12 week trail
evaluating the efficacy and safety of the
Fluticasone Propionate/Salmeterol
Diskus combination product
250/50mcg once daily
versus Fluticasone Propionate/Salmeterol
Diskus combination
product 100/50mcg twice daily versus
Fluticasone Propionate
Diskus 250mcg once daily versus placebo in
symptomatic adolescent
and adult subjects with asthma that is not
controlled on short
acting beta 2 agonists alone. GlaxoSmithKline.
Investigator. 2002.
AI424-045. A randomized,
open label study of the antiviral efficacy
and safety of atazanavir,
in combination with ritonavir or saquinavir,
and the combination
of lopinavir each with tenofovir and a
nucleoside in subjects
who have experienced virologic failure.
Bristol-Myers Squibb.
Investigator April 2002.
CFOR258D2307. A randomized,
multicenter, placebo controlled,
parallel group study,
of four month duration per patient, to evaluate
the safety and efficacy
of treatment with 24mcg bid and 12mcg bid
formoterol double
blind and 12mcg bid formoterol with additional on
demand formoterol
doses open label in adolescent and adult patients
with persistent stable
asthma. Novartis. Investigator. April 2002.
BI1182.52. Double-blind,
randomized, dose optimization trial of three
doses of tipranavir
boosted with low dose ritonavir (TPV/RTV) in
multiple antiretroviral
drug-experienced subjects. Boehringer
Ingelheim Pharmaceuticals,
Inc. Investigator. May 2002.
MEM-MD-06. Evaluation
of the long term safety and efficacy of
memantine in the treatment
of chronic pain in patients with painful
diabetic neuropathy.
Forest Laboratories. Investigator. June 2002.
AI424900. Atazanavir
(BMS-232632) for HIV infected indivuals: An
early access program.
Bristol-Myers Squibb. Investigator. July 2002.
MEM-MD-06B. Evaluation
of the long term safety and efficacy of
memantine in the treatment
of chronic pain in patients with painful
diabetic neuropathy.
Forest Laboratories. Investigator. 2002.
ZOL446H2310 (zoledronic
acid). Multinational, multicenter, double-
blind, randomized,
placebo controlled, parallel group study assessing
the efficacy of intravenous
zoledronic acid in preventing subsequent
osteoporotic fractures
after a hip fracture. Novartis. Investigator.
June 2002.
BI1182.17. A long
term open label rollover trial assessing the safety
and tolerability of
combination tipranavir and ritonavir use in HIV-1
infected subjects.
Boehringer Ingelheim Pharmaceuticals, Inc.
Investigator August
2002.
MEM-MD-06C. Evaluation
of the long term safety and efficacy of
memantine in the treatment
of chronic pain in patients with painful
diabetic neuropathy.
Forest Laboratories. Investigator. 2002.
MV16812. Multicenter,
open-label, early access program of fuzeon
(enfuvirtide T-20/Ro29-9800,
HIV-1 Fusion Inhibitor) in combination
with free choice antiretroviral
regimen to assess serious adverse
events, serious AIDS
defining events, and tolerability in patients
with advanced HIV-infection.
F. Hoffmann- LaRoche LTD, Trimeris
Inc., Investigator.
SAS30031. A randomized,
double-blind, 12 week trial evaluating the
safety of Fluticasone
Propionate/Salmerterol Diskus combinatin
product 100/50mcg
bid versus Fluticasone Propionate Diskus 100mcg
bid in symptomatic
pediatric subjects (4 – 11 years) with asthma.
GlaxoSmithKline. Principle
Investigator. 2002.
BY217/FK1 020. 12
week treatment with 250mcg Roflumilast versus
placebo in patients
with asthma. Byk Gulden Pharmaceuticals.
Principle Investigator.
2002.
BA16630B. Inhaled
corticosteroid replacement study- Efficacy and
safety of Ro- 27-2441
in moderate persistent asthma. Phase II.
Hoffmann La Roche.
Investigator. Dec. 2002.
BA16631B. Dose –ranging
study of Ro 27-2441 in patients with
persistent asthma
not treated with inhaled corticosteroids - Phase II.
Hoffman La Roche.
Investigator. Dec. 2002.
BI1182.12. Randomized,
open-label, comparative safety and efficacy
study of tipranavir
boosted with low-dose ritonavir (TPV/RTV)
versus genotypically-defined
protease inhibitor/ritonavir (PI/RTV) in
multiple antiretroviral
drug-experienced patients (RESIST-1:
Randomized Evaluation
of Strategic Intervention in Multi-Drug
ReSistant Patients
with Tipranavir). Boehringer Ingelheim
Pharmaceuticals, Inc.
Investigator. Jan 2003.
BI1182.51. An open
label, randomized, parallel group
pharmacokinetics trial
of tipranavir/ritonavir (TPV/RTV), alone or in
combination with RTV-boosted
saquinavir (SQV), amprenavir (APV)
or lopinavir (LPV),
plus an optimised background regimen, in multiple
antiretroviral (ARV)
experienced patients. Boehringer Ingelheim
Pharmaceuticals, Inc.
Investigator. Jan 2003.
CVAH631C2301. A randomized,
double-blind, multicenter, placebo-
controlled, parallel
group study to evaluate the efficacy and safety
of valsartan (320mg)
and hydrochlorothiazide (12.5mg and 25mg)
combined and alone,
valsartan 160mg and valsartan
160mg/hydrochorothiazide
12.5mg in hypertensive patients.
Novartis Pharmaceuticals.
Principle Investigator. 2003.
CVAH631C2301.Pharmacogenetic
Substudy . A randomized, double-
blind, multicenter,
placebo-controlled, parallel group study to
evaluate the efficacy
and safety of valsartan (320mg) and
hydrochlorothiazide
(12.5mg and 25mg) combined and alone,
valsartan 160mg and
valsartan 160mg/hydrochorothiazide 12.5mg in
hypertensive patients.
Novartis Pharmaceuticals. Principle
Investigator. 2003.
CVAH631C2301. A 54-week
open-label extension to a randomized,
double- blind, multicenter,
placebo-controlled, parallel group study to
evaluate the efficacy
and safety of valsartan (320mg) and
hydrochlorothiazide
(12.5mg and 25mg) combined and alone,
valsartan 160mg and
valsartan 160mg/hydrochorothiazide 12.5mg in
hypertensive patients.
Novartis Pharmaceuticals. Principle
Investigator. 2003.
A3841012. Clinical
utility of amlodipine/atorvastatin to improve
concomitant cardiovascular
risk factors of hypertension and
dyslipidemia (Gemini).
Pfizer. Principle Investigator. 2003.
BY217/M2-023. A randomized,
controlled study of roflumilast
(250mcg and 500mcg)
versus placebo in patients with asthma. A 24-
week, multinational,
double-blind, parallel group clinical study.
Altana. Principle
Investigator. 2003.
D5896C0005. A two-stage
randomized, open-label, parallel group,
phase III, multicenter,
7-month study to assess the efficacy and
safety of SYMBICORT“
pMDI administered either as fixed or as an
adjustable regimen
versus a fixed regimen of Advair‰ in subjects 12
years of age and older
with asthma. Astra Zeneca. Principle
Investigator. 2003.
C02-009. A phase III,
randomized, multicenter, allopurinol and
placebo- controlled
study assessing the safety and efficacy of oral
febuxostat in subjects
with gout. TAP Pharmaceuticals. Principle
Investigator. 2003.
CCIB002 K2302. A randomized,
double-blind, multicenter, positive
controlled, parallel
group study to evaluate the safety and efficacy
of Lotrel (amlodipine/benazepril)
compared to Zestorectic
(lisinopril/hydrochlorothiazide)
in hypertensive patients. Novartis
Pharmaceuticals. Priniciple
Investigator. 2003.
066-00. A randomized,
double-blind, active-comparator-controlled,
parallel-group study
to evaluate the safety of etoricoxib in patients
with osteoarthritis
or rheumatoid arthritis. Merke. Principle
Investigator. 2003.
A multicenter, randomized,
double-blind, placebo-controlled,
“factorial”design
study to evaluate the lipid-altering efficacy and
safety of ezetimibe/simvastatin
combination tablet in patients with
primary hypercholesterolemia.
Merke. Principle Investigator. 2003.
References available upon request
top